THE IMPACT OF COMBINED ADMINISTRATION OF SEROTONINSPECIFIC REUPTAKE INHIBITORS WITH ATORVASTATIN ON THE LIVER AND KIDNEYS. IN VITRO AND IN VIVO STUDIES
MARIOLA HERBET, MAGDALENA IZDEBSKA, MONIKA GAWROŃSKA-GRZYWACZ*, IWONA PIĄTKOWSKA-CHMIEL, JAROSŁAW DUDKA
Department of Toxicology, Medical University of Lublin, 8B Jaczewski Street, Lublin 20-090, Poland
*corresponding author: monika.grzywacz@umlub.pl
Download Full Article

Abstract:
In the treatment of depression coexisting with cardiovascular disease, serotonin-specific reuptake inhibitors (SSRIs) are the
most frequently prescribed in combination with statins used for treating hypercholesterolemia in the primary and secondary
prevention of cardiovascular and cerebrovascular incidents. Because of a risk of adverse interactions between abovementioned
drugs, our research was aimed to assess the impact of combined administration of SSRIs (fluoxetine or
paroxetine) and atorvastatin on the physiological kidney cell culture and the functions of liver and kidneys in rats. The results
of in vitro assays suggest an adverse effect of combination of fluoxetine and atorvastatin on cell viability. Conversely, the
results of in vivo experiments indicate this combination superior safety profile in comparison to atorvastatin coupled with
paroxetine. The adverse effect observed may point out the possibility of minor liver and kidney disorders during the longterm
treatment with paroxetine and atorvastatin.

Top